menu

The Role of Adjuvanted Flu Vaccines for Older High-Risk Patients

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Unraveling the Role of Adjuvanted Flu Vaccines for Older High-Risk Patients

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Tune in to learn how routine vaccinations against the flu, especially with adjuvanted vaccines, could have a significant impact on preventing severe complications and deaths in older adult patients.

Please See

Important Safety Information

  • Sponsored by

  • Overview

    Influenza disproportionately affects adults 65 and older as a result of increased frequency of comorbidities and immunosenescence.1,2 And it’s also linked to neurologic, cardiovascular, and respiratory complications in high-risk groups, while potentially exacerbating underlying chronic medical conditions.1,2 So how can adjuvanted vaccines help patients who are affected? Dive in to learn more with Dr. Stephen Pelton, Professor of Pediatrics at Boston University Chobanian and Avedisian School of Medicine.

    References:

    1. Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA.
    2. Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023; 11(10):1525. https://doi.org/10.3390/vaccines11101525

    USA-FLUD-23-0011 12/23

  • FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)

    INDICATION AND IMPORTANT SAFETY INFORMATION

    INDICATIONS AND USAGE
    FLUAD® QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older.

    This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS
    Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

    WARNINGS AND PRECAUTIONS    
    If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks. 

    Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

    Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

    The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

    Vaccination with FLUAD QUADRIVALENT may not protect all vaccine recipients against influenza disease.

    ADVERSE REACTIONS
    The most common (≥ 10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%). Other adverse events may occur. 

    To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.  

    Before administration, please see the full Prescribing Information for FLUAD QUADRIVALENT.

    FLUAD® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

Schedule28 Feb 2024